AnaptysBio, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 128.72 million compared to USD 57.8 million a year ago. Basic loss per share from continuing operations was USD 4.57 compared to USD 2.11 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.64 USD | -1.23% | +1.37% | +10.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.55% | 654M | |
+14.25% | 118B | |
+12.71% | 106B | |
-3.91% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.19% | 15.56B | |
+4.06% | 13.63B | |
+27.32% | 12.27B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022